A randomized, placebo-controlled clinical trial of tacrolimus ophthalmic suspension 0.1% in severe allergic conjunctivitis

Journal of Ocular Pharmacology and Therapeutics

Volumn 26, Issue 2, 2010, Pages 165-173

  Ohashi, Yuichi ^a   Ebihara, Nobuyuki ^b   Fujishima, Hiroshi ^c   Fukushima, Atsuki ^d   Kumagai, Naoki ^e   Nakagawa, Yayoi ^f   Namba, Kenichi ^g   Okamoto, Shigeki ^h   Shoji, Jun ⁱ   Takamura, Etsuko ^j   Hayashi, Kunihiko ^k  

^a EHIME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b JUNTENDO UNIVERSITY   (Japan)

^c International University of Health and Welfare Mita Hospital   (Japan)

^d KOCHI MEDICAL SCHOOL   (Japan)

^e Kumagai Eye Clinic   (Japan)

^f Nakagawa Eye Clinic   (Japan)

^g HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^h Okamoto Eye Clinic   (Japan)

ⁱ NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^j TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^k GUNMA UNIVERSITY   (Japan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMLEXANOX; BETAMETHASONE; CROMOGLYCATE DISODIUM; DEXAMETHASONE; FLUOROMETHOLONE; IBUDILAST; KETOTIFEN FUMARATE; LEVOCABASTINE; PEMIROLAST; PLACEBO; TACROLIMUS;

ADOLESCENT; ALLERGIC CONJUNCTIVITIS; ARTICLE; ATOPIC DERMATITIS; CHEMOSIS; CHILD; CLINICAL TRIAL; CONJUNCTIVA FOLLICLE; CONJUNCTIVAL HYPEREMIA; CONJUNCTIVITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORNEA EROSION; CORNEA LIMBUS; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EYE DISCHARGE; EYE IRRITATION; EYE PAIN; FEMALE; FOREIGN BODY REACTION; GIANT PAPILLARY CONJUNCTIVITIS; HERPES SIMPLEX KERATITIS; HUMAN; LACRIMATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OCULAR PRURITUS; PHOTOPHOBIA; PRESCHOOL CHILD; PUNCTATE KERATITIS; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; THROAT IRRITATION; TREATMENT OUTCOME; VERNAL CONJUNCTIVITIS; VISUAL ACUITY; VISUAL ANALOG SCALE;

ADOLESCENT; CONJUNCTIVITIS, ALLERGIC; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; MALE; OPHTHALMIC SOLUTIONS; SICKNESS IMPACT PROFILE; TACROLIMUS; TREATMENT OUTCOME;

EID: 77951678229     PISSN: 10807683     EISSN: None     Source Type: Journal    
DOI: 10.1089/jop.2009.0087     Document Type: Article

References (23)

1. Bonini, S., Bonini, S., Lambiase, A., et al. Vernal keratoconj unctivitis revisited: a case series of 195 patients with long-term followup. Ophthalmology. 107: 1157-1163, 2000.
2. Tabbara, K. F. Ocular complications of vernal keratoconj unctivitis. Can. J. Ophthalmol. 34: 88-92, 1999.
3. Foster, C. S., and Calonge, M. Atopic keratoconj unctivitis. Ophthalmology. 97: 992-1000, 1990.
4. BenEzra, D., Pe'er, J., Brodsky, M., et al. Cyclosporine eyedrops for the treatment of severe vernal keratoconjunctivitis. Am. J. Ophthalmol. 101: 278-282, 1986. (Pubitemid 16132651)
5. BenEzra, D., Matamoros, N., and Cohen, E. Treatment of severe vernal keratoconjunctivitis with cyclosporine A eyedrops. Transplant. Proc. 20: 644-649, 1988.
6. Secchi, A. G., Tognon, M. S., and Leonardi, A. Topical use of cyclosporine in the treatment of vernal keratoconjunctivitis. Am. J. Ophthalmol. 110: 641-645, 1990.
7. Bleik, J H., and Tabbara, K. F. Topical Cyclosporine in Vernal Keratoconjunctivitis. Ophthalmology. 98: 1679-1684, 1991.
8. Hingorani, M., Moodaley, L., Calder, V. L., et al. A randomized, placebo-controlled trial of topical cyclosporin A in steroid-dependent atopic keratoconj unctivitis. Ophthalmology. 105: 1715-1720, 1998. (Pubitemid 28513525)
9. Pucci, N., Novembre, E., Cianferoni, A., et al. Effi cacy and safety of cyclosporine eyedrops in vernal keratoconjunctivitis. Ann. Allergy Asthma Immunol. 89: 298-303, 2002.
10. Akpek, E K., Dart, J. K., Watson, S., et al. A randomized trial of topical cyclosporin 0.05% in topical steroidresistant atopic keratoconjunctivitis. Ophthalmology. 111: 476-482, 2004. (Pubitemid 38293102)
11. Ozcan, A. A., Ersoz, T. R., and Dulger, E. Management of severe allergic conjunctivitis with topical cyclosporin a 0.05% eyedrops. Cornea. 26: 1035-1038, 2007. (Pubitemid 47480680)
12. Daniell, M., Constantinou, M., Vu, H. T., et al. Randomised controlled trial of topical ciclosporin A in steroid dependent allergic conjunctivitis. Br. J. Ophthalmol. 90: 461-464, 2006.
13. Kino, T., Hatanaka, H., Hashimoto, M., et al. FK-506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physico-chemical and biological characteristics. J. Antibiot. 40: 1249-1255, 1987. (Pubitemid 17138109)
14. Kino, T., Hatanaka, H., Miyata, S., et al. FK-506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in vitro. J. Antibiot. 40: 1256-1265, 1987. (Pubitemid 17138110)
15. Vichyanond, P., Tantimongkolsuk, C., Dumrongkigchaiporn, P., et al. Vernal keratoconj unctivitis: Result of a novel therapy with 0.1% topical ophthalmic FK-506 ointment. J. Allergy Clin. Immunol. 113: 355-358, 2004. (Pubitemid 38210564)
16. Joseph, M. A., Kaufman, H. E., and Insler, M. Topical tacrolimus ointment for treatment of refractory anterior segment infl ammatory disorders. Cornea. 24: 417-420, 2005. (Pubitemid 40586629)
17. Virtanen, H. M., Reitamo, S., Kari, M., et al. Effect of 0. 03% tacrolimus ointment on conjunctival cytology in patients with severe atopic blepharoconjunctivitis: a retrospective study. Acta. Ophthalmol. Scand. 84: 693-695, 2006. (Pubitemid 44317552)
18. Kymionis, G. D., Goldman, D., Ide, T., et al. Tacrolimus ointment 0.03% in the eye for treatment of giant papillary conjunctivitis. Cornea. 27: 228-229, 2008. (Pubitemid 351158746)
19. Miyazaki, D., Tominaga, T., Kakimaru-Hasegawa, A., et al. Therapeutic effects of tacrolimus ointment for refractory ocular surface infl ammatory diseases. Ophthalmology. 115: 988-992. e5, 2008. (Pubitemid 351749679)
20. Attas-Fox, L., Barkana, Y., Iskhakov, V., et al. Topical tacrolimus 0.03% ointment for intractable allergic conjunctivitis: an openlabel pilot study. Curr. Eye Res. 33: 545-549, 2008. (Pubitemid 351948486)
21. Uchio, E., Kimura, R., Migita, H., et al. Demographic aspects of allergic ocular diseases and evaluation of new criteria for clinical assessment of ocular allergy. Graefes Arch. Clin. Exp. Ophthalmol. 246: 291-296, 2008. (Pubitemid 351149635)
22. Kang, S., Lucky, A. W., Pariser, D., et al. Long-term safety and effi cacy of tacrolimus ointment for the treatment of atopic dermatitis in children. J. Am. Acad. Dermatol. 44: S58-S64, 2001 (Pubitemid 32047913)
23. Hanifi n, J. M., Paller, A. S., Eichenfi eld, L., et al.; US Tacrolimus Ointment Study Group. Effi cacy and safety of tacrolimus ointment treatment for up to 4 years in patients with atopic dermatitis. J. Am. Acad. Dermatol. 53: S186-S194, 2005.